Dr. Nicholas Geisse is the Chief Science Officer at Curi Bio and a co-founder of Kinea Bio, both spin-outs of the University of Washington. He has a B.A., Biochemistry and Molecular Biology from Boston University, Ph.D. in Pharmacology from Cambridge University, and did his postdoctoral fellowship at Harvard. Previously, he was a research scientist, project manager, and product manager at Asylum Research (later acquired by Oxford Instruments) where he was responsible for sales and marketing, design, production, profitability, and new product introduction and development. At Curi, he is specifically tasked with guiding the overall scientific strategy of the company in addition to developing and bringing to market Curi’s next-generation of innovative products aimed at increasing the predictive power of in vitro cell based assays. Nick and his team have been honored by being awarded Xconomy’s 2020 ‘Big Idea’ award, the US Small Business Administration’s 2020 Tibbetts award, and a 2021 Edison Award.
Nicholas Geisse, PhD